Consensus Spyre Therapeutics, Inc.

Equities

SYRE

US00773J2024

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-13 pm EDT			5-day change	1st Jan Change
39.89 ^USD	-1.29%		-0.65%	+21.76%

Mar. 11	Spyre Therapeutics, Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-09-2026 08:40 AM
Mar. 11	Spyre Therapeutics, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 03:10 PM

Evolution of the Average Target: Spyre Therapeutics, Inc.

Evolution of the Target Price: Spyre Therapeutics, Inc.

Changes in Analyst Recommendations: Spyre Therapeutics, Inc.

db3077dca8b6828471488773ca.2TSlHvtiA2YMJM-UJQMCr255K21-Yx6_UETwH6qV8gE.qUzsWasLLi9VXLz_EmRsnTwcHllPVWn4aA-FRc2gtHa2AfBRvwhBNEdxjg~cac35fc47da3c3d3056b0c8b8ce626ea

Analysts' recommendations: Spyre Therapeutics, Inc.

Feb. 23	Deutsche Bank Adjusts Spyre Therapeutics PT to $55 From $45, Maintains Buy Rating	MT
Dec. 18	Mizuho Initiates Spyre Therapeutics at Outperform With $53 Price Target	MT
Dec. 17	Citigroup Initiates Spyre Therapeutics at Buy With $64 Price Target	MT
Nov. 06	Deutsche Bank Adjusts Spyre Therapeutics Price Target to $42 From $43, Maintains Buy Rating	MT
25-10-14	Spyre Therapeutics Inc - Expects $486.2 million in cash and equivalents as of Sept 30, 2025 - SEC filing	RE
25-09-26	Deutsche Bank Initiates Spyre Therapeutics at Buy With $43 Price Target	MT
25-04-08	Leerink Partners Initiates Spyre Therapeutics With Outperform Rating, $45 Price Target	MT
25-03-18	Wolfe Research Initiates Spyre Therapeutics at Outperform With $27 Price Target	MT
24-12-11	JonesTrading Initiates Spyre Therapeutics at Hold	MT
24-09-04	Wedbush Initiates Spyre Therapeutics at Outperform With $45 Price Target	MT
24-07-16	Evercore ISI Starts Spyre Therapeutics With Outperform Rating	MT
24-05-13	Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating	MT
24-05-02	Baird Starts Spyre Therapeutics With Outperform Rating, $50 Price Target	MT
24-03-26	Stifel Adjusts Spyre Therapeutics' Price Target to $54 From $36, Maintains Buy Rating	MT
24-03-01	Wells Fargo Upgrades Spyre Therapeutics to Overweight From Equalweight, Raises Price Target to $35 From $12	MT
23-12-20	BTIG Initiates Spyre Therapeutics With Buy Rating, Price Target is $32	MT
23-12-18	Stifel Adjusts Price Target on Spyre Therapeutics to $27 From $23, Keeps Buy Rating	MT
23-12-11	Jefferies Initiates Spyre Therapeutics at Buy Rating With $31 Price Target	MT
23-08-16	Wells Fargo Adjusts Price Target on Aeglea BioTherapeutics to $0.50 From $0.35, Maintains Equal-Weight Rating	MT
23-07-25	Stifel Initiates Aeglea BioTherapeutics With Buy Rating, $0.90 Price Target	MT
23-04-12	LifeSci Capital Downgrades Aeglea BioTherapeutics to Market Perform From Outperform	MT
23-04-12	JonesTrading Downgrades Aeglea BioTherapeutics to Hold From Buy	MT
22-10-28	Piper Sandler Lifts Aeglea BioTherapeutics to Overweight From Neutral, Price Target to $1.50 From $1	MT
22-10-28	Wells Fargo Lifts Aeglea BioTherapeutics to Overweight From Equalweight, Price Target to $2 From $1.50	MT
22-06-03	Needham Downgrades Aeglea BioTherapeutics to Hold From Buy	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	SPYRE THERAPEUTICS, INC.					+46.83%
	ARGENX SE					+37.03%
	WUXI APPTEC CO., LTD.					+46.5%
	INSMED INCORPORATED					+52.35%
	BIONTECH SE					+42.05%
	WUXI BIOLOGICS (CAYMAN) INC.					+30.59%
	GENMAB A/S					+30.97%
	AKESO, INC.					+58.36%
	SUMMIT THERAPEUTICS INC.					+94.72%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+36%
	Average					+47.54%
	Weighted average by Cap.					+45.38%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

39.89USD

Average target price

58.57USD

Spread / Average Target

+46.83%

High Price Target

70.00USD

Spread / Highest target

+75.48%

Low Price Target

47.00USD

Spread / Lowest Target

+17.82%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Deutsche Bank Securities
Mizuho Securities
Citigroup
Leerink Partners
Wolfe Research
JonesTrading Institutional Services
Wells Fargo Securities
Baird
Stifel Nicolaus
BTIG
Jefferies & Co.
LifeSci Capital
Piper Sandler
Needham & Co.
HC Wainwright